### <u>Materials Design Analysis Reporting (MDAR)</u> Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

## **Materials**

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
For commercial reagents, provide supplier	TTI1 (SANTA CRUZ, sc-365119) Figure 4B&4c	
name, catalogue number and RRID, if available.	GAPDH (Cell Signal Technology, #5174) Figure 4B	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: Provide species information, strain.	Caco-2:CHu146, the Type Culture Collection of Chinese	
Provide accession number in repository <b>OR</b>	Academy of Sciences; HT-29: TCHu103, the Type Culture	
supplier name, catalog number, clone number,	Collection of Chinese Academy of Sciences	
OR RRID	Figure 5E&5F	
Primary cultures: Provide species, strain, sex of		n/a
origin, genetic modification status.		

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: Provide species, strain, sex, age, genetic modification status. Provide accession number in repository <b>OR</b> supplier name, catalog number, clone number, <b>OR</b> RRID		n/a
Animal observed in or captured from the field: Provide species, sex and age where possible		n/a
Model organisms: Provide Accession number in repository (where relevant) OR RRID		n/a

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
<b>Plants:</b> provide species and strain, unique accession number if available, and source (including location for collected wild specimens)		n/a
<b>Microbes:</b> provide species and strain, unique accession number if available, and source		n/a

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes(Army Medical University;Table 1)	
Provide statement confirming informed consent obtained from study participants.	Yes(Department of General Surgery, The Second Affiliated Hospital, Army Medical University: Table 1)	
Report on age and sex for all study participants.	Yes(Department of General Surgery, The Second Affiliated Hospital, Army Medical University: Table 1)	

# <u>Design</u>

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number <b>OR</b> cite DOI in manuscript.	Yes(clinical trial register no.ChiCTR2000033078:Figure 4A)	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
Provide DOI or other citation details if detailed step-	Yes(doi: 10.3389/fimmu.2019.00806 ;Material and	
by-step protocols are available.	methods)	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been		n/a
done, or if they were not carried out.		
Sample size determination		n/a
Randomisation		n/a
Blinding		n/a
Inclusion/exclusion criteria		n/a

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	3 times	
Define whether data describe technical or biological replicates	Technical replicates	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Yes(Our work was approved by the ethics committee of the Army Medical University.clinical trial register no.ChiCTR2000033078; Material and methods)	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.		n/a
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.		n/a

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern,		n/a
state the authority granting approval and reference		
number for the regulatory approval		

# <u>Analysis</u>

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is		n/a
excluded, and whether the criteria for exclusion were		
determined and specified in advance.		

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Yes{two-tailed Student t test(to determine if there is a significant difference between the means of two group);Pearson's correlation coefficients(to measure the linear relationship between two variables in a sample; Material and methods)}	.,,

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available,		n/a
including protocols for access or restriction on		
access.		
If data are publicly available, provide accession	Yes(GSE44076; GSE32323; GSE21510; Material and	
number in repository or DOI or URL.	methods&Results)	
If publicly available data are reused, provide	Yes(GSE44076; GSE32323; GSE21510; Material and	
accession number in repository or DOI or URL, where	methods&Results)	
possible.		

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential	Yes(GraphPad Prism 8; R 3.6.1; Cytoscape3.7.2; Materia	
for replicating the main findings of the study:	and methods)	
State whether the code or software is available.	Yes(Results)	
If code is publicly available, provide accession number in repository, or DOI or URL.	Yes(R WCGNA package doi: 10.1186/1471-2105-9-559. R limma package doi:10.1093/nar/gkv007;Referrences)	

## Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of		
discipline-specific guidelines, established and		
endorsed through community initiatives. Journals		
have their own policy about requiring specific		
guidelines and recommendations to complement		
MDAR.		
State if relevant guidelines (eg., ICMJE, MIBBI,	ICMJE guidelines were followed, as the journal follows	
ARRIVE) have been followed, and whether a checklist	ICMJE recommendations for publication.	
(eg., CONSORT, PRISMA, ARRIVE) is provided with		
the manuscript.		

 $Article\ information:\ http://dx.doi.org/10.21037/tcr-20-3322$